Is There a Difference between Levodopa/ Dopa-Decarboxylase Inhibitor and Entacapone and Levodopa/Dopa-Decarboxylase Inhibitor Dose Fractionation Strategies in Parkinson’s Disease Patients Experiencing Symptom Re-Emergence due to Wearing-Off?

By  

European Neurology, Vol. 61, Iss. 2, 2008-11 ,pp. : 69-75

Karger

Access to resources Recommend Favorite

Efficacy and Tolerability of Entacapone as Adjunctive Therapy to Levodopa in Patients with Parkinson’s Disease and End-of-Dose Deterioration in Daily Medical Practice: An Open, Multicenter Study

By  

European Neurology, Vol. 45, Iss. 2, 2001-02 ,pp. : 111-118

Karger

Access to resources Recommend Favorite

Pharmacokinetic Studies with a Dual-Release Formulation of Levodopa, a Novel Principle in the Treatment of Parkinson’s Disease

By  

European Neurology, Vol. 39, Iss. 2, 1998-02 ,pp. : 119-124

Karger

Access to resources Recommend Favorite

Five-Year Follow-Up of Early Lisuride and Levodopa Combination Therapy versus Levodopa Monotherapy in de novo Parkinson’s Disease

By  

European Neurology, Vol. 44, Iss. 1, 2000-07 ,pp. : 22-30

Karger

Access to resources Recommend Favorite

Impaired Gastric Myoelectrical Activity in Patients with Parkinson's Disease and Effect of Levodopa Treatment

By Lu Ching-Liang   Shan Din-E   Chen Chih-Yen   Luo Jiing-Chyuan   Chang Full-Young   Lee Shou-Dong   Wu Han-Chang   Chen J. D. Z.  

Digestive Diseases and Sciences, Vol. 49, Iss. 5, 2004-05 ,pp. : 744-749

Springer Publishing Company

Access to resources Recommend Favorite